Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Inflation data disappoints markets
Mon, 16 Sep 01:30 pm

Indian equity markets have fallen in the last 2 hours of trade and are trading in red. This seems to be largely attributable to disappointing wholesale price inflation (WPI) number which was up at 6.1% from 5.8% in July 2013. The headline inflation rose at the fastest pace in last six months, this was largely driven by the surge in food prices. Most sectors are trading in red barring the stocks from Banking, Auto and FMCG space.

BSE-Sensex is down by 13 points and NSE-Nifty is trading down by 16 points. While BSE Mid Cap is trading down by 0.83%, BSE Small Cap index is trading down by 0.73%. The rupee is trading at 62.75 to the US dollar.

Majority of the steel stocks are trading in the green with JSW Steel and Maharashtra Seamless being the biggest gainers. As per a leading financial daily, Steel Authority of India Ltd (SAIL) is contemplating setting up a special steel venture with Japan's Kobe Steel. The steel thus manufactured would be utilized in the defence sector or automobiles. This will be SAIL's second joint venture with Kobe which is a pioneer in special steel. SAIL had signed a Memorandum of Understanding (MOU) with Kobe last year for 0.5 m tonne iron nugget plant using the ITMK3 technology. This project will come up at the company's alloy steel plant in Durgapur. SAIL is on an expansion and modernization drive and is expected to have an installed steel capacity of 19 m tonnes by the end of FY14. As per the company, expansion of its Bhilai plant will take place in FY15 and raise its capacity to 23.5 m tonnes. However, the company has deferred its long term target of 50 m tonnes hot metal capacity from 2020 to 2025. This is in line with the government's target of 300 m tonnes of installed capacity by 2025. Reportedly, the installed capacity in the country stands around 90 m tonnes. SAIL has said that project financing is the biggest challenge in realizing the target set and has sought government aid in this regard. The stock is currently trading flat.

Most of the Indian pharma stocks are trading in red with Ranbaxy Ltd and Wockhardt Ltd being the top losers. Sun pharmaceuticals Ltd, has received approval for lansoprazole, delayed released capsules of strength 15mg and 30mg. The said drug is bioequivalent to Takeda's Prevacid brand. Reportedly, the US market size of this drug is $430 m per annum. Prevacid is indicated for short term treatment (4 weeks) for healing and symptoms of active duodenal ulcer. With this approval, Sun pharma now has total 320 ANDAs (Abbreviated new drug application) and approximatley 133 drugs await approval. Some Indian generic companies viz Dr Reddy's, Natco pharma, Wockhardt Ltd and Zydus healthcare are also having approval for the drug. One should also note that Prevacid 15mg is also sold by some companies as an over the counter (OTC)drug in the US market.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary


What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "Inflation data disappoints markets". Click here!

  

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project (Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Mar 8, 2021 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS